Loading company…
Phrenix Therapeutics develops GPCR-targeted therapies for psychiatric, cognitive, and neurological conditions.
Phrenix Therapeutics uses structure-guided design and pharmacology to develop treatments for psychiatric and neurological disorders. The Australian company was founded in 2022 by Chris Langmead (CEO), Greg Stewart, and Jess Nithianantharajah. In February 2025, it raised an undisclosed amount of Seed funding from Curie.Bio and Brandon Capital Partners to advance its drug discovery pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in